Ten-year follow-up from the randomized LIR!C trial showed that ileocecal resection is superior to infliximab (Remicade) for achieving sustained clinical remissions in patients with ileal Crohn's disease. The study was published in Lancet Gastroenterology and Hepatology. Crohn's disease is a chronic systemic inflammatory disease of the digestive tract, diagnosed on the basis of history, clinical picture, endoscopic, radiological and laboratory examinations. More than 30% of patients are resistant to treatment and require corticoids or immunosuppressants. 5-ASA treatment is effective in the mild form, with a dose of 4 g/day in the acute phase and 2–3 g/day for maintenance. Biological treatment such as infliximab or adalimumab is indicated for refractory course or fistulas, with an effectiveness of up to 70% and mucosal healing in 30% of patients. Endoscopy with histopathology is key to confirm the diagnosis and differentiate it from ulcerative colitis. Laboratory tests include CRP, stool calprotectin, and ultrasound to monitor inflammation in the terminal ileum.